在IRIS注册研究中接受单一抗VEGF药物治疗1年的年龄相关性黄斑变性患者的真实世界视力
基于美国眼科学会IRIS注册研究的回顾性非随机比较研究,纳入2013至2016年间接受贝伐珠单抗、雷珠单抗或阿柏西普单药治疗1年的新生血管性年龄相关性黄斑变性患者13859例。结果显示三种药物在1年单药治疗中改善视力相似,多变量校正后1年logMAR视力变化无统计学差异。
要点
- 雷珠单抗组和阿柏西普组1年平均注射次数高于贝伐珠单抗组(6.4次和6.2次 vs 5.9次,P<0.0001)。
- 年龄校正模型显示雷珠单抗和阿柏西普1年logMAR视力优于贝伐珠单抗,但多变量校正后差异不显著。
- 贝伐珠单抗组1年视力提高≥3行的患者比例高于雷珠单抗组(22.7% vs 20.1%,P=0.0093)和阿柏西普组(22.7% vs 17.8%,P<0.0001)。
主要发现
- 13859例患者中,6723例接受贝伐珠单抗,2749例接受雷珠单抗,4387例接受阿柏西普单药治疗1年,共完成84828次注射。
- 1年平均注射次数(标准差)雷珠单抗组为6.4(±2.4)次,阿柏西普组为6.2(±2.4)次,均高于贝伐珠单抗组的5.9(±2.4)次(P<0.0001)。
- 年龄校正模型中,雷珠单抗组和阿柏西普组1年logMAR视力分别为0.50(±0.49)和0.49(±0.44),优于贝伐珠单抗组的0.55(±0.57)(P<0.0001);多变量校正(年龄、基线视力、糖尿病、玻璃体后脱离、注射次数、种族、保险)后差异不显著。
- 年龄校正或多变量校正后,1年平均logMAR视力变化(标准差)在各治疗组间无统计学差异:贝伐珠单抗组-0.048(0.44),雷珠单抗组-0.053(0.46),阿柏西普组-0.040(0.39);P=0.46。
- 1年视力提高≥3行的患者比例贝伐珠单抗组为22.7%,高于雷珠单抗组的20.1%(P=0.0093)和阿柏西普组的17.8%(P<0.0001);多变量校正后,仅阿柏西普相较于贝伐珠单抗显示更高的≥3行视力丧失对数比值比(1.25 log odds ratio;P<0.0016)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study is to compare real-world visual acuity (VA) in patients with neovascular age-related macular degeneration (nAMD) treated with a single anti-vascular endothelial growth factor (VEGF) drug monotherapy for 1 year from the American Academy of Ophthalmology (AAO) Intelligent Research in Sight (IRIS) Registry. DESIGN: Retrospective, nonrandomized, comparative study. PARTICIPANTS: IRIS Registry patients with nAMD who received bevacizumab, ranibizumab, or aflibercept only for 1 year between 2013-2016. METHODS: Participants were divided into 3 groups based on monotherapy type. Multivariate analysis of covariance models (ANCOVA) was constructed in a stepwise fashion. MAIN OUTCOME MEASURES: The logarithm of the minimum angle of resolution (logMAR) VA at 1 year and mean change in logMAR VA between baseline and 1 year were compared between drug types. RESULTS: Of 13 859 patients, 6723 received bevacizumab, 2749 received ranibizumab, and 4387 received aflibercept only for 1 year. A total of 84 828 injections were performed. The mean number of injections (standard deviation) at 1 year was higher in the ranibizumab (6.4 [±2.4]) and aflibercept groups (6.2 [±2.4]) compared to bevacizumab group (5.9 [±2.4]; P < 0.0001). In the age-adjusted model, both ranibizumab and aflibercept achieved better logMAR VA at 1 year compared with bevacizumab (0.50 [±0.49], 0.49 [±0.44], 0.55 [±0.57]; P < 0.0001). However, this difference was not significant after multivariate adjustment (age, baseline VA, diabetes, posterior vitreous detachment, number of injections, race, insurance). There was no statistical difference in the age-adjusted or multivariate-adjusted mean logMAR VA change (standard deviation) at 1 year among treatment groups (-0.048 [0.44] bevacizumab, -0.053 [0.46] ranibizumab, -0.040 [0.39] aflibercept; P = 0.46). A higher percentage of patients achieved a ≥3-line VA improvement at 1 year in the bevacizumab group (22.7%) compared with ranibizumab (20.1%; P = 0.0093) and aflibercept (17.8%; P < 0.0001). However, after multivariate adjustment, aflibercept exhibited a greater log odds of a ≥3-line VA loss compared with bevacizumab only (1.25 log odds ratio; P < 0.0016). CONCLUSIONS: This study suggests that all 3 drugs improve VA similarly over 1 year of monotherapy.
引用
- Rao P, Lum F, Wood K, et al. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. Ophthalmology. 2017. PMID: 29146306. doi:10.1016/j.ophtha.2017.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。